ArticleJournal of traditional and complementary medicine2026
Role of IGF1/IGFR signaling pathway in neuroprotective effect of Shengmai Dihuang Decoction on CIH-induced cognitive impairment.
Article in Journal of traditional and complementary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As the most important pathophysiological process of obstructive sleep apnea (OSA), chronic intermittent hypoxia (CIH) could cause cognitive impairment. Our previous study showed that Shengmai Dihuang Decoction (SDD) improved CIH-induced cognitive impairment. However, the precise underlying mechanism remains unclear. Objective: This study aims to investigate the role of the insulin-like growth factor 1 (IGF1)/insulin-like growth factor 1 receptor (IGFR) signaling pathway in improving CIH-induced neuronal injury by SDD treatment. Methods: In this study, HT22 cells were cultured under CIH conditions (O Results: Results showed that cell activity was decreased during CIH exposure, followed by mitochondrial damage and decreased IGF1/IGFR expressions. Exogenous IGF1 treatment increased cell activity and improved mitochondrial dysfunction. SDD treatment increased IGF1/IGFR expressions, activated the RAS/RAF/MAPK and PI3K/AKT signaling pathways, increased ERK/CREB/BDNF and postsynaptic density protein 95 (PSD-95) expressions, and improved mitochondrial damage and cell activity. IGF1 siRNA or AG1024 (IGFR antagonist) reversed the protective effects of SDD under CIH condition. Conclusion: Results suggest that SDD alleviates CIH-induced neuronal injury, mainly by improving mitochondrial damage via activation of IGF1/IGFR signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.